Clinical trials: Wilms Tumor
Neoplasms, Breast
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer.
- Trial name
- INDUCT (NCT01220128)
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Aromatase inhibitor, 5-Fluorouracil
- Where
- 36 sites in United States, Belgium and 5 more
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline